Skip to main content
    • Aa
    • Aa

Improving population health or the population itself? Health technology assessment and our genetic future

  • Ken Bassett (a1), Patricia M. Lee (a2), Carolyn J. Green (a1), Lisa Mitchell (a3) and Arminée Kazanjian (a1)...

The province of British Columbia (BC), Canada is developing its first population-wide prenatal genetic screening program, known as triple-marker screening (TMS). TMS, initiated with a simple blood test, is most commonly used to screen for fetuses with the chromosomal abnormality known as Down syndrome or neural tube disorders. Women testing TMS-positive are offered diagnostic amniocentesis and, if the diagnosis is confirmed, selective second-trimester abortion. The project described in this study was initiated to address the broad range of issues arising from this testing technology and provides an example of the new type of health technology assessment (HTA) contribution emerging (and likely to become increasing necessary) in health policy development. With the advent of prenatal genetic screening programs, would-be parents gain the promise of identifying target conditions and, hence, the option of selective abortion of affected fetuses. There is considerable awareness that these developments pose challenges in every dimension (ethical, political, economic, and clinical) of the health-care environment. In the effort to construct an appropriate prenatal screening policy, therefore, administrators have understandably sought guidance from within the field of HTA. The report authors concluded that, within the restricted path open to it, the role of government is relatively clear. It has the responsibility to maintain equal access to prenatal testing, as to any other health service. It should also require maintenance of medical standards and evaluation of program performance. At the same time, policy-makers need actively to support those individuals born with disabilities and their families.

Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

AschA. 1999Prenatal diagnosis and selective abortion: A challenge to practice and policy. Am J Public Health. 89: 16491657.

BaillieC, HewisonJ. 1999Antenatal screening: Obtaining selective consent to scanning, rather than screening, is possible. Letter. BMJ. 318: 805.

GillM, MurdayV, SlackJ. 1987An economic appraisal of screening for Down syndrome in pregnancy using maternal age and serum alpha feto-protein concentration. Soc Sci Med. 24: 725731.

HoweDT, GornallR, WellesleyD, BoyleT, BarberJ. 2000Six year survey of screening for Down's syndrome by maternal age and mid-trimester ultrasound scans. BMJ. 320: 606610.

LippmanA. 1999Embodied knowledge and making sense of prenatal diagnosis. J Genet Counseling. 8: 255274.

MerzB. 1987Matchmaking scheme solves Tay-Sacks problem. JAMA. 258: 26362639.

PalomakiGE, KnightGJ, McCarthyJE, HaddowJE, DonhoweJM. 1997Maternal serum screening for Down syndrome in the United States: A 1995 survey. Am J Obstet Gynecol. 176: 10461051.

PressN, BrownerC. 1998Characteristics of women who refuse an offer of prenatal diagnosis: Data from the California maternal serum alpha fetoprotein blood test experience. Am J Med Genet. 78: 433445.

PressN, BrownerC. 1993Collective fictions: Similarities in reasons for accepting maternal serum alpha-fetoprotein screening among women of diverse ethnic and social class backgrounds. Fetal Diagn Ther. 8(Suppl 1): 97106.

RappR. 1993Sociocultural differences in the impact of amniocentesis: An anthropological research report. Fetal Diagn Ther. 8(Suppl 1): 9096.

SadovnickAD, BairdPA. 1983A cost-benefit analysis of a population screening programme for neural tube defects. Prenat Diagn. 3: 117126.

SadovnickAD, BairdPA. 1981A cost-benefit analysis of prenatal detection of Down's syndrome and neural tube defects in older mothers. Am J Med Genet. 10: 367378.

SheldonTA, SimpsonJ. 1991Appraisal of a new scheme for prenatal screening for Down's syndrome. BMJ. 302: 11331136.

SmithDK, ShawRW, MarteauTM. 1994Informed consent to undergo serum screening for Down's syndrome: The gap between policy and practice. BMJ. 309: 776.

WaldNJ, WattHC, HackshawAK. 1999Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med. 341: 461467.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Full text views

Total number of HTML views: 2
Total number of PDF views: 5 *
Loading metrics...

Abstract views

Total abstract views: 49 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 29th May 2017. This data will be updated every 24 hours.